09.20.18
Avalon GloboCare Corp. has officially commenced operation of Epicon Biotech Co. Ltd. (“Epicon”), a joint venture with Jiangsu Unicorn Biological Technology Co. Ltd., located within the Nanjing BenQ Hospital - a prestigious Grade 3A medical center in Jiangsu Province, China.
Epicon occupies a 16,000 square foot, state-of-the-art Good Manufacturing Practice laboratory space for processing, biobanking and preparation of clinical-grade products for cellular therapy. Epicon also plans to establish a joint biomedical institute with Nanjing BenQ Hospital to further expand the platform. One of the major initiatives for Epicon is to establish the world’s largest aqueous humor derived exosome bio-bank to advance the next-generation of diagnosis and Therapeutics for ophthalmologic diseases. Several prominent and internationally recognized ophthalmologists have agreed to contribute to this endeavor.
As previously announced in June 2018, Avalon formed a joint venture with Jiangsu Unicorn to establish a provincial network of translational cellular therapies and BIO -banking programs.
Epicon occupies a 16,000 square foot, state-of-the-art Good Manufacturing Practice laboratory space for processing, biobanking and preparation of clinical-grade products for cellular therapy. Epicon also plans to establish a joint biomedical institute with Nanjing BenQ Hospital to further expand the platform. One of the major initiatives for Epicon is to establish the world’s largest aqueous humor derived exosome bio-bank to advance the next-generation of diagnosis and Therapeutics for ophthalmologic diseases. Several prominent and internationally recognized ophthalmologists have agreed to contribute to this endeavor.
Epicon also aims to enhance the translational research and clinical development of standardization, Validation , processing, bio-production, and international collaboration with respect to a wide repertoire of cellular therapies, including stem Cell , Chimeric Antigen Receptor (CAR)-T, CAR-Natural Killer (CAR-NK) cell, T Cell Receptor-T (TCR-T) adoptive immunotherapy, allogeneic NK cell, invariant NKT cell, as well as Endothelial Cell (EC).
“We are very excited to commence operation of Epicon in China. This state-of-the-art platform serves well to accelerate our international programs in exosome technology, cellular therapeutics and bio-banking,” stated David Jin, M.D., Ph.D., chief executive officer and president of Avalon GloboCare Corp. “This joint venture will strengthen our core technological capabilities and help further establish our leadership in the fields of cellular therapy, regenerative medicine and exosome-based biobanking,”
